Sanofi - Sanofi successfully prices EUR 1.8 billion bond issue

OREANDA-NEWS. Sanofi announces that it has successfully priced its offering of EUR 1.8 billion of notes across 3 tranches:

  • EUR 500 million Fixed Rate Notes, due 2019, bearing interest at an annual rate of 0.000%
  • EUR 600 million Fixed Rate Notes, due 2024, bearing interest at an annual rate of 0.625%
  • EUR 700 million Fixed Rate Notes, due 2028, bearing interest at an annual rate of 1.125%

The issue is drawn under the Company's Euro Medium Term Note Programme.

The transaction enables the Group to lower its average cost of debt and extend the average maturity of its debt.

Sanofi intends to use the net proceeds of the offering for general corporate purposes, including the repayment of existing borrowings.

Barclays, Citi, ING, Royal Bank of Scotland and Santander were Bookrunners for the offering.

About Sanofi
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).